Zentalis Pharmaceuticals Inc
Затворен
3.7 4.82
Преглед
Промяна на цената на акция
24 ч
Минимум
3.51
Максимум
3.84
Приходи | -42M -78M |
|---|---|
EPS | -0.59 |
Служители | 106 |
EBITDA | -42M -77M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +148.03% upside |
Следващи печалби | 6.11.2026 г. |
|---|
Пазарна капитализация | -34M 297M |
|---|---|
Предишно отваряне | -1.12 |
Предишно затваряне | 3.7 |
Zentalis Pharmaceuticals Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Zentalis Pharmaceuticals Inc Прогноза
Ценова цел
By TipRanks
148.03% нагоре
12-месечна прогноза
Среден 8.83 USD 148.03%
Висок 11 USD
Нисък 5 USD
Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zentalis Pharmaceuticals Inc през последните три месеца.
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
